Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.
Journal: Postgraduate medicine
Published: June 13, 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
Journal: Diabetes, obesity & metabolism
Published: January 15, 2026
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: December 02, 2025
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
Journal: The New England journal of medicine
Published: September 11, 2025
Managing Adverse Effects of Incretin-Based Medications for Obesity.
Journal: JAMA
Published: July 29, 2025
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Journal: The New England journal of medicine
Published: June 22, 2025
The health burden of obesity in women: a call to action for OB-GYN HCPs.
Journal: Menopause (New York, N.Y.)
Published: May 30, 2025
Talking about obesity in the OB-GYN clinic.
Journal: Menopause (New York, N.Y.)
Published: May 30, 2025
Treating obesity to optimize women's health outcomes.
Journal: Menopause (New York, N.Y.)
Published: May 30, 2025
Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.
Journal: Contemporary clinical trials communications
Published: May 08, 2025
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
Journal: Diabetes, obesity & metabolism
Published: September 23, 2024
Last Updated: 09/26/2026